What is JAGX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.00B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for JAGX?

P/E (TTM) is n/a and 52-week range is $2.03 to $1118.25 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s JAGX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for JAGX?

The company profile lists revenue (TTM) near $74M, net income (TTM) near -$9.63B, EPS (TTM) near -$370.63 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Jaguar Health Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Francisco, California, US, 2.1M shares outstanding, ISIN US47010C8543 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Jaguar Health Inc

$JAGX

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Jaguar Health Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in San Francisco, California and currently employs 47 full-time employees. The company went IPO on 2015-05-13. Jaguar Health, Inc. is a commercial stage pharmaceuticals company. The firm is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. The company has an exclusive distribution agreement for the sale of Gelclair. The company is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health.

Employees

Website

jaguar.health/

IPO

2015-05-13

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US47010C8543

Headquarters

San Francisco, California, US

Shares outstanding

2.1M

NAICS sector

Manufacturing

Institutional ownership

0.11%

Browse other companiesFree AI scores and summaries for more stocks